Health AI Central
Share:
Peer-Reviewed Publication
Nat Rev Drug Discov2026;25(7):534-552.July 1, 2026Journal Article

Target identification and assessment in the era of AI.

Frank W Pun1, Dmitriy Podolskiy2, Evgeny Izumchenko3, Andrew Mortlock4, Tudor I Oprea5, Morten Scheibye-Knudsen6, Kristen Fortney7, Eric Morgen7, Feng Ren1,8, Alex Zhavoronkov9,10,11,12,13
1Insilico Medicine Hong Kong Ltd., Hong Kong SAR, China.
2Astellas Institute for Regenerative Medicine, Astellas Pharma Inc., Westborough, MA, USA.
3Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, IL, USA.
4Astellas Pharma Europe EHQ Ltd, Addlestone, UK.
5Expert Systems Inc., San Diego, CA, USA.
6Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
7BioAge Labs, Emeryville, CA, USA.
8Insilico Medicine Shanghai Ltd., Shanghai, China.
9Insilico Medicine Hong Kong Ltd., Hong Kong SAR, China. alex@insilico.com.
10Insilico Medicine Shanghai Ltd., Shanghai, China. alex@insilico.com.
11Insilico Medicine AI Ltd., Masdar City, Abu Dhabi, UAE. alex@insilico.com.
12Insilico Medicine US Inc., Cambridge, MA, USA. alex@insilico.com.
13Buck Institute for Research on Aging, Novato, CA, USA. alex@insilico.com.
PubMed DOI

Abstract

Drug discovery and development is time-intensive, expensive and laden with risk. Identifying the right drug targets is crucial for increasing the probability of success, but traditional target identification and validation often take years, and a target is only fully validated once a drug based on it receives approval by regulatory agencies. Given its proficiency in analysing large datasets and in…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.